Current and future therapeutic approaches in locally advanced (stage III) non-small cell lung cancer

Angela Davies, David R Gandara, Primo N Lara, Zelanna Goldberg, Peter Roberts, Derick H Lau

Research output: Contribution to journalArticle

11 Scopus citations

Abstract

In the treatment of locally advanced (stage III) non-small cell lung cancer, randomized clinical trials have shown that sequential administration of platinum-based chemotherapy followed by radiotherapy improves outcome compared with radiotherapy alone. More recently, concurrent chemoradiotherapy has been shown to be superior to sequential therapy. Incorporating full-dose chemotherapy into induction or consolidation phases is aimed at the eradication of distant micrometastases. These approaches are currently being examined in clinical trials. The role of neoadjuvant and adjuvant therapy in resectable stage IIIA patients remains controversial. Integration of newer cytotoxic agents (paclitaxel, docetaxel, gemcitabine, vinorelbine, and irinotecan) and molecularly targeted agents into the treatment of stage-III patients may result in improved long-term outcomes and is currently under study.

Original languageEnglish (US)
Pages (from-to)10-16
Number of pages7
JournalSeminars in Oncology
Volume29
Issue number3 SUPPL. 12
StatePublished - 2002

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Current and future therapeutic approaches in locally advanced (stage III) non-small cell lung cancer'. Together they form a unique fingerprint.

  • Cite this